Indian businesses are significantly expanding their UK presence, with company numbers soaring by nearly 60% and combined revenues exceeding...

Markets traded subdued with the India VIX correcting nearly 15% this week, though this hasn't significantly impacted benchmark index moveme...

Zydus Lifesciences increased its share buyback price to Rs 1,260 per share while reducing the repurchase size to 87.3 lakh shares. The tota...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Nifty closed marginally higher last week, driven by IT and energy stocks, as markets brace for key events. Technical analysts suggest Nifty...

Indian markets navigated a sideways trend, with analysts urging caution until the 24,000 mark is reclaimed. Key stocks like Lenskart, Apoll...

Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...

Indian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL,...

Zydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astel...

Zydus Lifesciences will be in focus on Wednesday after receiving final USFDA approval for its Verapamil Hydrochloride Extended-Release Tabl...

Shares of Zydus Lifesciences are likely in focus after its subsidiary, ZyVet Animal Health, launched the first FDA-approved generic treatme...

Zydus Lifesciences signed an exclusive licensing and supply deal with Netherlands-based Synthon BV to commercialize generic Ozanimod Capsul...

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week's approval for...

Zydus Lifesciences shares rose nearly 2% to Rs 899.40 after receiving USFDA approval to manufacture Eluxadoline Tablets (75 mg & 100 mg) fo...

JM Financial maintains a hold rating on Zydus Lifesciences, setting a target price of Rs 1,090. The quarterly income has dropped by 15.40% ...

Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a 'Buy' rating, citing the strength of the company’s US pipeline as a ma...

Bullish ABC breakout suggests follow through moves on P&F chart.